Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
|
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
  • [21] Angiotensin II Type 1 Receptor Blocker Combined with Calcium Channel Blocker for the Treatment of Obese Hypertensive Patients
    Miura, Shin-ichiro
    Saku, Keijiro
    INTERNAL MEDICINE, 2009, 48 (01) : 1 - 2
  • [22] Combination Therapy of Calcium Channel Blocker and Angiotensin II Receptor Blocker Reduces Augmentation Index in Hypertensive Patients
    Doi, Masayuki
    Miyoshi, Toru
    Hirohata, Satoshi
    Kamikawa, Shigeshi
    Usui, Shinichi
    Kaji, Youko
    Sakane, Kosuke
    Ogawa, Hiroko
    Ninomiya, Yoshifumi
    Kusachi, Shozo
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2010, 339 (05): : 433 - 439
  • [24] Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy
    Ma, Jin
    Wang, Xiao-Yan
    Hu, Zhi-De
    Zhou, Zhi-Rui
    Schoenhagen, Paul
    Wang, Hao
    JOURNAL OF THORACIC DISEASE, 2015, 7 (12) : 2243 - 2252
  • [25] Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation
    Kario, Kazuomi
    Hoshide, Satoshi
    Uchiyama, Kazuaki
    Yoshida, Tetsuro
    Okazaki, Osamu
    Noshiro, Takao
    Aoki, Hirotaka
    Mizuno, Hiroyuki
    Matsumoto, Yuri
    JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (10): : 1036 - 1044
  • [26] The beyond effects of antihypertensive drug on diabetes, using calcium channel blocker and angiotensin II receptor blocker
    Uno, Y.
    Morita, H.
    Ikeda, T.
    Mori, I.
    Fujioka, K.
    Okada, H.
    Fujikake, T.
    Miyauchi, R.
    Kajita, K.
    Ishizuka, T.
    DIABETOLOGIA, 2009, 52 : S467 - S468
  • [27] Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease
    Nutahara, K
    Higashihara, E
    Horie, S
    Kamura, K
    Tsuchiya, K
    Mochizuki, T
    Hosoya, T
    Nakayama, T
    Yamamoto, N
    Higaki, Y
    Shimizu, T
    NEPHRON CLINICAL PRACTICE, 2005, 99 (01): : C18 - C23
  • [28] Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan
    Iwai, Masarsu
    Li, Huan-Sheng
    Chen, Rui
    Shiuchi, Tetsuya
    Wu, Lan
    Min, Li-Juan
    Li, Jian-Mei
    Tsuda, Masahiro
    Suzuki, Jun
    Tomono, Yumiko
    Tomochika, Hirokazu
    Mogi, Masaki
    Horiuchi, Masatsugu
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03): : 1081 - 1087
  • [29] Olmesartan, an Angiotensin II Receptor Blocker, Restores Cerebral Hypoperfusion in Elderly Patients With Hypertension
    Nagata, Riya
    Kawabe, Kiyokazu
    Ikeda, Ken
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2010, 19 (03): : 236 - 240
  • [30] Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy
    Hsueh, Willa A.
    Shojaee, Ali
    Maa, Jen-Fue
    Neutel, Joel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (11) : 1809 - 1818